ALNY NASDAQ
Alnylam Pharmaceuticals, Inc.
1W: -2.4%
1M: -11.1%
3M: -21.1%
YTD: -43.1%
1Y: -50.9%
3Y: +41.8%
5Y: +11.7%
$226.79
-0.87 (-0.38%)
After Hours: $226.09 (-0.70, -0.31%)
Weekly Expected Move ±5.6%
$199
$211
$224
$237
$249
Credit Risk of going bust: lower than 72% of companies Debt: 4.0% of company value Bonds: $81.8M held by 45 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.82 (down 99.6%), Alnylam Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $1.27B against a stock market value of $30.46B.
Distance to default 7.98 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $505.5M (short-term plus half of long-term), stock volatility 51.3%; Altman Z'' 1.62. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.82 (down 99.6%), Alnylam Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $1.27B against a stock market value of $30.46B.
Distance to default 7.98 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $505.5M (short-term plus half of long-term), stock volatility 51.3%; Altman Z'' 1.62. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
2 relationships2
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2023-07-26
Earliest Filing
2023-07-26
Latest Filing
partner: 2
Counterparties (Filed by ALNY)
2 relationshipsCompanies named in ALNY's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd. | — | partner | Entered into a collaboration and license agreement for joint development of zilebesiran products. | 2023-07-26 | View |
| Genentech, Inc. | — | partner | Entered into a collaboration and license agreement for joint development of zilebesiran products. | 2023-07-26 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-30 | Earnings Release; Exhibits | View | |
| 2026-05-27 | Officer/Director Change; Shareholder Vote | View | |
| 2026-04-30 | Earnings Release; Exhibits | View | |
| 2026-03-04 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-02-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition | View | |
| 2025-12-11 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-03 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-09-12 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-09-10 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-18 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-05-13 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-05-01 | Financial Statements and Exhibits | View | |
| 2025-03-21 | Other Events | View | |
| 2025-03-05 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-02-13 | Financial Statements and Exhibits | View | |
| 2025-01-13 | Results of Operations and Financial Condition | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR